Patents by Inventor Cyrus Ohnmacht

Cyrus Ohnmacht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lactams and uses thereof
    Patent number: 7858776
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: December 28, 2010
    Assignee: AstraZeneca AB
    Inventors: Bruce Thomas Dembofsky, Robert Jacobs, Cyrus Ohnmacht
  • NOVEL LACTAMS AND USES THEREOF
    Publication number: 20100160627
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Application
    Filed: January 26, 2009
    Publication date: June 24, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Bruce Thomas Dembofsky, Robert Jacobs, Cyrus Ohnmacht
  • Novel Lactams And Uses Thereof
    Publication number: 20080076752
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Application
    Filed: August 24, 2007
    Publication date: March 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Christopher Becker, Bruce Dembofsky, Robert Jacobs, James Kang, Cyrus Ohnmacht, James Rosamond, Ashokkumar Shenvi, Thomas Simpson, James Woods
  • Lactams and uses thereof
    Patent number: 7294622
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: November 13, 2007
    Assignee: Astrazeneca AB
    Inventors: Christopher Becker, Bruce Dembofsky, Robert Jacobs, James Kang, Cyrus Ohnmacht, James Rosamond, Ashokkumar Bhikkappa Shenvi, Thomas Simpson, James Woods
  • Neurokinin antagonists for use as medicaments
    Patent number: 7235541
    Abstract: The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: June 26, 2007
    Assignee: Astrazeneca AB
    Inventors: Jeffrey Scott Albert, Peter Bernstein, Cyrus Ohnmacht, Jr., Keith Russell, Ashokkumar Bhikkappa Shenvi
  • Compounds and Uses Thereof
    Publication number: 20070142328
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Cyrus Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce Dembofsky
  • Compounds and Uses Thereof
    Publication number: 20070142382
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Cyrus Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce Dembofsky
  • New neurokinin antagonists for use as medicaments
    Publication number: 20070021406
    Abstract: The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor.
    Type: Application
    Filed: January 24, 2005
    Publication date: January 25, 2007
    Inventors: Jeffrey Albert, Peter Bernstein, Cyrus Ohnmacht, Keith Russell, Ashokkumar Shenvi
  • Novel lactams and uses thereof
    Publication number: 20060089346
    Abstract: Compounds having the formula (1) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid B protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 27, 2006
    Applicant: AstraZeneca AB
    Inventors: Christopher Becker, Bruce Dembofsky, Robert Jacobs, James Kang, Cyrus Ohnmacht, James Rosamond, Ashokkumar Shenvi, Thomas Simpson, James Woods
  • Neurokinin antagonists for use as medicaments
    Patent number: 6846814
    Abstract: Compounds having the general formula wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z and n are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: January 25, 2005
    Assignee: Astra Zeneca AB
    Inventors: Jeffrey Scott Albert, Peter Bernstein, Cyrus Ohnmacht, Jr., Keith Russell, Ashokkumar Bhikkappa Shenvi
  • Neurokinin antagonists for use as medicaments
    Publication number: 20030158170
    Abstract: A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
    Type: Application
    Filed: October 2, 2002
    Publication date: August 21, 2003
    Inventors: Jeffrey Scott Albert, Peter Bernstein, Cyrus Ohnmacht Jr, Keith Russell, Ashokkumar Bhikkappa Shenvi